Trastuzumab emtansine(Synonyms: 曲妥珠单抗-美坦新偶联物; Ado-Trastuzumab emtansine; PRO132365; T-DM 1)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Trastuzumab emtansine (Synonyms: 曲妥珠单抗-美坦新偶联物; Ado-Trastuzumab emtansine; PRO132365; T-DM 1) 纯度: ≥99.40%

Trastuzumab emtansine (Ado-Trastuzumab emtansine) 是一种抗体偶联药物 (ADC)，其结合了 HER2 靶向的曲妥珠单抗的抗肿瘤特性以及微管抑制剂 DM1 的细胞毒活性。Trastuzumab emtansine 可用于晚期乳腺癌的研究。

Trastuzumab emtansine(Synonyms: 曲妥珠单抗-美坦新偶联物; Ado-Trastuzumab emtansine; PRO132365; T-DM 1)

Trastuzumab emtansine Chemical Structure

CAS No. : 1018448-65-1

规格 价格 是否有货 数量
1 mg ￥4800 In-stock
5 mg ￥16000 In-stock
10 mg ￥26000 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

生物活性

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer[1][2].

体外研究
(In Vitro)

Trastuzumab emtansine (2 μg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Trastuzumab emtansine (15 mg/kg; i.v. three to five times weekly for 3 weeks) exhibits significantly anti-tumor effect in mice[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CB-17/SCID mice (6 weeks) were injected with OVA10 cells[2]
Dosage: 15 mg/kg
Administration: I.v. three to five times weekly for 3 weeks
Result: Showed remarkable inhibition of tumor growth in mice and was well tolerated.

Clinical Trial

CAS 号

1018448-65-1
中文名称

曲妥珠单抗-美坦新偶联物
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Verma S, et, al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91.

    [2]. Menderes G, et, al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017 Oct;147(1):145-152.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务